Atamestane
 | |
| Clinical data | |
|---|---|
| Other names | SH-489; Metandroden; 1-Methylandrosta-1,4-diene-3,17-dione |
| Routes of administration | By mouth[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C20H26O2 |
| Molar mass | 298.426 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
  (what is this?) (verify) | |
Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer.[2] It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.[3][additional citation(s) needed]
See also
- Boldione (androsta-1,4-diene-3,17-dione)
References
- ^ Etreby, M. Fathy El; Nishino, Yukishige; Habenicht, Ursula‐F.; Henderson, David (1991-11-12). "Atamestane, a New Aromatase Inhibitor for the Management of Benign Prostatic Hyperplasia". Journal of Andrology. 12 (6): 403–414. doi:10.1002/j.1939-4640.1991.tb00283.x. ISSN 0196-3635.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 794–. ISBN 978-1-4757-2085-3.
- ^ el Etreby MF (March 1993). "Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review". The Journal of Steroid Biochemistry and Molecular Biology. 44 (4–6): 565–72. doi:10.1016/0960-0760(93)90260-4. PMID 7682838. S2CID 53256276.
External links
- Atamestane entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |